{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-25-000048","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2025-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.607382+00:00","generated_at":"2026-05-16T19:12:33.900426+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Akebia amends Medice license to supply vadadustat and grant manufacturing rights","bullets":["Amendment #1 to License Agreement signed Nov 12, 2025 with MEDICE Arzneimittel Putter GmbH & Co. KG.","Akebia agrees to supply vadadustat drug substance under a concurrent supply agreement.","Medice granted right to manufacture Vafseo tablets using supplied drug substance.","Any know-how or patent rights from Medice's manufacturing owned by Akebia."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-25-000048","json":"https://secwatch.observer/filing/0001517022-25-000048.json","markdown":"https://secwatch.observer/filing/0001517022-25-000048.md","text":"https://secwatch.observer/filing/0001517022-25-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000048/0001517022-25-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000048/akba-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:12:33.900426+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}